NCT01956110.

6, † , for the ESTHER-2 Study Group KEY MESSAGEFollitropin delta can be safely used for repeated ovarian stimulation, shown by its low immunogenicity potential and sustained safety in an expanded dose range. The trial also confirms the appropriateness of the follitropin delta dosing regimen in repeated cycles, with documented efficacy in terms of ovarian response, pregnancy and live birth rates.

No abstract

The objective of this study was to evaluate oral supplements with antioxidants in oocyte and embryonic quality in patients undergoing assisted reproductive treatments. A cohort of 120 patients was included in the study: 60 patients were included in the control group and 60 in the Seidivid group. The medication contained folic acid, myo-inositol, melatonin, and selenium (Seidivid) and was supplied for at least 2 months before the ovarian puncture. The results of the different cycles were compared, evaluating the number of follicles (9.67 vs 9.15, P = .584), the number of metaphase II (8.52 vs 8.53, P = .986), the number of embryos of A + B quality, the number of vitrified embryos (1.93 vs 2.26, P = .505), and biochemical (62.75% vs 66.00%, P = .83) and clinical pregnancy rates (52.94% vs 56.00%, P = .84). A significant fact in our study was that although the supplements with antioxidants were not statistically significant for some aspects, they were significant in terms of obtaining embryos of good quality (A + B).

No abstract